Cargando…

Circulating non-coding RNA-biomarker potential in neoadjuvant chemotherapy of triple negative breast cancer?

Due to the positive association between neoadjuvant chemotherapy (NACT) and the promising early response rates of patients with triple negative breast cancer (TNBC), including probabilities of pathological complete response, NACT is increasingly used in TNBC management. Liquid biopsy-based biomarker...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ritter, Andrea, Hirschfeld, Marc, Berner, Kai, Rücker, Gerta, Jäger, Markus, Weiss, Daniela, Medl, Markus, Nöthling, Claudia, Gassner, Sandra, Asberger, Jasmin, Erbes, Thalia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6910196/ https://www.ncbi.nlm.nih.gov/pubmed/31789396 http://dx.doi.org/10.3892/ijo.2019.4920

Ejemplares similares

Evaluation of circulating microRNAs as non-invasive biomarkers in the diagnosis of ovarian cancer: a case–control study
por: Berner, Kai, et al.
Publicado: (2021)

Endoxifen and fulvestrant regulate estrogen-receptor α and related DEADbox proteins
por: Asberger, Jasmin, et al.
Publicado: (2020)

Anticarcinogenic Effects of Odorant Substances Citral, Citrathal R and Cyclovertal on Breast Cancer in vitro
por: Klauser, Anna-Lena, et al.
Publicado: (2021)

Feasibility of urinary microRNA detection in breast cancer patients and its potential as an innovative non-invasive biomarker
por: Erbes, Thalia, et al.
Publicado: (2015)

Neoadjuvant chemotherapy in breast cancer significantly reduces number of yielded lymph nodes by axillary dissection
por: Erbes, Thalia, et al.
Publicado: (2014)

In Vitro microRNA Expression Profile Alterations under CDK4/6 Therapy in Breast Cancer
por: Asberger, Jasmin, et al.
Publicado: (2023)

Alternative splicing of synuclein gamma in endometrial cancer: identification of a novel isoform
por: Schaal, Kathrin, et al.
Publicado: (2015)

Exometabolom analysis of breast cancer cell lines: Metabolic signature
por: Willmann, Lucas, et al.
Publicado: (2015)

HNRNP G and HTRA2-BETA1 regulate estrogen receptor alpha expression with potential impact on endometrial cancer
por: Hirschfeld, Marc, et al.
Publicado: (2015)

Circulating immune cell dynamics in patients with triple negative breast cancer treated with neoadjuvant chemotherapy
por: Talamantes, Sarah, et al.
Publicado: (2020)

The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
por: Johnson, Kai Conrad Cecil, et al.
Publicado: (2023)

Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer
por: Cavallone, Luca, et al.
Publicado: (2020)

Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review
por: van den Ende, Nadine S., et al.
Publicado: (2023)

Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: An Observational Study
por: Shao, Zhiying, et al.
Publicado: (2016)

The use of colour-coded and spectral Doppler ultrasound in the differentiation of benign and malignant breast lesions.
por: Peters-Engl, C., et al.
Publicado: (1995)

Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030
por: Parsons, Heather A., et al.
Publicado: (2023)

The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer
por: Castrellon, Aurelio Bartolome, et al.
Publicado: (2017)

Immune responses during neoadjuvant chemotherapy in triple negative breast cancer
por: Ghallab, Ahmed
Publicado: (2020)

Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer
por: Ding, Feng, et al.
Publicado: (2022)

Detection of respiratory viruses using a multiplex real-time PCR assay in Germany, 2009/10
por: Bierbaum, Sibylle, et al.
Publicado: (2013)

Heterogeneity of Circulating Tumor Cells in Neoadjuvant Chemotherapy of Breast Cancer
por: Kaigorodova, Evgeniya V., et al.
Publicado: (2018)

Simpson's paradox visualized: The example of the Rosiglitazone meta-analysis
por: Rücker, Gerta, et al.
Publicado: (2008)

Ranking treatments in frequentist network meta-analysis works without resampling methods
por: Rücker, Gerta, et al.
Publicado: (2015)

Presenting simulation results in a nested loop plot
por: Rücker, Gerta, et al.
Publicado: (2014)

Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
por: Goel, Arun Kumar, et al.
Publicado: (2010)

BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
por: Tanino, Hirokazu, et al.
Publicado: (2016)

Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy
por: Castaneda, Carlos A, et al.
Publicado: (2016)

Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: Jung, Yoon Yang, et al.
Publicado: (2016)

Transcriptome Meta-Analysis of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy
por: Zhang, Wei, et al.
Publicado: (2023)

The Response of Triple-Negative Breast Cancer to Neoadjuvant Chemotherapy and the Epithelial–Mesenchymal Transition
por: Zapperi, Stefano, et al.
Publicado: (2023)

Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy
por: Chen, Yu-Hsiang, et al.
Publicado: (2017)

High Numbers and Densities of PD1(+) T-Follicular Helper Cells in Triple-Negative Breast Cancer Draining Lymph Nodes Are Associated with Lower Survival
por: Bronsert, Peter, et al.
Publicado: (2020)

Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
por: Santonja, Angela, et al.
Publicado: (2018)

Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer
por: Nakashoji, Ayako, et al.
Publicado: (2017)

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
por: Lehmann, Brian D., et al.
Publicado: (2016)

Comment on “Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer”
por: Altundag, Kadri
Publicado: (2017)

ITPKC as a Prognostic and Predictive Biomarker of Neoadjuvant Chemotherapy for Triple Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

Clinical Observation of Zhengyuan Capsule Combined with Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
por: Zhang, Xiaoyu, et al.
Publicado: (2022)

Neoadjuvant Chemotherapy Combined with Breast-Conserving Surgery in the Treatment of Triple-Negative Breast Cancer
por: Zhang, Xiaoyu, et al.
Publicado: (2022)

Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy
por: Li, Zhijun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_km1b1ev3qmqjhqi8spav95la02